Equities Analysts Set Expectations for ABEO Q4 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Equities researchers at HC Wainwright boosted their Q4 2025 earnings estimates for shares of Abeona Therapeutics in a research report issued on Tuesday, March 10th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn ($0.41) per share for the quarter, up from their prior estimate of ($0.42). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.97) EPS.

ABEO has been the subject of several other research reports. Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Oppenheimer reiterated an “outperform” rating on shares of Abeona Therapeutics in a report on Monday. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Abeona Therapeutics Trading Down 1.2%

NASDAQ:ABEO opened at $4.95 on Thursday. The business’s 50-day moving average is $5.13 and its two-hundred day moving average is $5.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.74 and a quick ratio of 9.53. Abeona Therapeutics has a 12 month low of $3.93 and a 12 month high of $7.54. The firm has a market capitalization of $268.24 million, a PE ratio of 4.02 and a beta of 1.13.

Institutional Trading of Abeona Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. AIGH Capital Management LLC acquired a new position in Abeona Therapeutics during the 4th quarter worth $10,540,000. Boone Capital Management LLC bought a new stake in shares of Abeona Therapeutics in the 2nd quarter worth about $7,126,000. Tang Capital Management LLC acquired a new stake in shares of Abeona Therapeutics in the 4th quarter valued at about $5,270,000. Geode Capital Management LLC lifted its position in shares of Abeona Therapeutics by 129.1% during the second quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after purchasing an additional 623,243 shares during the last quarter. Finally, Aberdeen Group plc bought a new position in shares of Abeona Therapeutics during the fourth quarter worth about $3,248,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Insiders Place Their Bets

In other Abeona Therapeutics news, Director Christine Berni Silverstein sold 20,070 shares of Abeona Therapeutics stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $5.09, for a total transaction of $102,156.30. Following the sale, the director directly owned 137,722 shares in the company, valued at $701,004.98. The trade was a 12.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Leila Alland sold 18,065 shares of Abeona Therapeutics stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $5.09, for a total value of $91,950.85. Following the sale, the director owned 173,614 shares in the company, valued at $883,695.26. This represents a 9.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 209,605 shares of company stock valued at $1,101,300. Insiders own 6.90% of the company’s stock.

Abeona Therapeutics News Summary

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $20 price target while slightly raising its FY2025 EPS view to $1.23 (from $1.22), which supports the bullish thesis despite other cuts. HC Wainwright Reaffirms Buy Rating for Abeona Therapeutics (NASDAQ:ABEO)
• Neutral Sentiment: Short-interest notices show “large increases” in March filings but the reported figures are internally inconsistent (0 shares / NaN changes and a 0.0 days ratio), making the short-interest signal unreliable for trading decisions today.
• Negative Sentiment: HC Wainwright materially lowered 2026 quarterly and full‑year EPS estimates in its March 10 report — examples include Q1 2026 to ($0.31) from ($0.23), Q2 to ($0.27) from ($0.21), Q3 to ($0.20) from ($0.02) and FY2026 to ($0.97) (from prior forecasts much less negative). Those downward revisions increase near-term earnings uncertainty and likely weigh on the stock. HC Wainwright Reaffirms Buy Rating for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.